Glycomet 500 mg SR

Product Overview

Glycomet 500 mg SR is an extended‑release tablet formulated to support glycemic control in adults with type 2 diabetes mellitus. According to the National Institutes of Health, metformin is a first‑line therapy for type 2 diabetes. Produced by USV Pvt Ltd, each strip contains twenty tablets delivering a consistent 500 mg dose of the biguanide agent. The product is available in pack sizes of 100, 200, and 300 tablets, providing flexible options for long‑term therapy. Designed for once‑daily administration, the sustained‑release matrix helps maintain steady plasma concentrations, reducing the frequency of dosing and improving adherence. This medication is classified under the broader category of diabetes care and is intended for oral use only.

What is Glycomet 500 mg SR

Glycomet 500 mg SR contains metformin hydrochloride, a biguanide oral hypoglycemic agent widely prescribed for type 2 diabetes. The drug belongs to the class of glucose‑lowering medications that decrease hepatic glucose production and increase peripheral insulin sensitivity. Unlike immediate‑release formulations, the sustained‑release (SR) version releases the active compound gradually over 24 hours, allowing a single daily dose to achieve stable therapeutic levels. This pharmacokinetic profile reduces gastrointestinal side effects commonly associated with metformin and supports continuous glycemic management throughout the day. The tablet is film‑coated to protect the drug from gastric acid, ensuring optimal absorption in the small intestine. This formulation also contributes to a lower peak concentration, which may improve tolerability.

Uses and Benefits

Glycomet 500 mg SR is indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes mellitus in patients who require additional glycemic control. The extended‑release technology provides a steady plasma concentration, which translates into more consistent blood‑glucose lowering effects compared with multiple daily dosing of immediate‑release tablets. Clinical studies have demonstrated that patients receiving metformin SR achieve a mean reduction in HbA1c of approximately 1.5 % when combined with lifestyle modifications. In addition, the formulation is associated with modest weight neutrality and does not increase the risk of hypoglycemia when used alone. Metformin SR has also been associated with modest improvements in cardiovascular risk markers, such as reduced triglyceride levels, and can be taken with or without food, offering added flexibility for patients with varied daily routines.

How It Works

The active moiety of Glycomet 500 mg SR, metformin, exerts its glucose‑lowering effect primarily in the liver by inhibiting hepatic gluconeogenesis, the process by which new glucose is produced. Additionally, the drug enhances peripheral insulin sensitivity, facilitating greater glucose uptake by skeletal muscle and adipose tissue. Metformin also modulates intestinal glucose absorption and alters the composition of the gut microbiota, contributing to its overall antidiabetic activity. The sustained‑release matrix ensures a gradual release of the drug, maintaining therapeutic levels that support continuous suppression of hepatic glucose output and promotion of insulin‑mediated glucose utilization. This balanced approach helps to lower fasting and post‑prandial blood‑glucose concentrations without causing excessive hypoglycemia. The medication activates AMP‑activated protein kinase (AMPK), a cellular energy sensor that further impairs gluconeogenic pathways and improves insulin signaling, reinforcing its glucose‑lowering action. This enzymatic activation also contributes to modest weight stability and may reduce hepatic lipid accumulation.

Dosage Guidelines

For most adults with type 2 diabetes, the recommended starting dose of Glycomet 500 mg SR is one tablet taken once daily with the evening meal to minimize gastrointestinal discomfort. The dose may be titrated upward in increments of 500 mg at intervals of at least four weeks, guided by blood‑glucose monitoring and physician assessment, up to a maximum of 2000 mg per day (four tablets). Patients with renal impairment should initiate therapy at a reduced dose and may require periodic dose adjustments based on estimated glomerular filtration rate (eGFR). It is essential to swallow the tablet whole; crushing or chewing may compromise the sustained‑release mechanism.

Side Effects

Common adverse reactions associated with Glycomet 500 mg SR include gastrointestinal disturbances such as nausea, diarrhea, abdominal cramping, and occasional metallic taste. These effects are generally mild to moderate and tend to diminish with continued therapy as the body adapts to the medication. Less frequently, patients may experience vitamin B12 deficiency, manifested as fatigue or peripheral neuropathy, which can be mitigated through periodic laboratory monitoring. Rare but serious complications such as lactic acidosis have been reported, particularly in individuals with significant renal dysfunction, hepatic disease, or conditions predisposing to hypoxia. FDA labeling provides further details. Immediate medical attention is advised if unexplained muscle pain, rapid breathing, or dizziness develops.

Warnings and Precautions

Patients should inform their healthcare provider of any history of kidney disease, heart failure, or pulmonary conditions before initiating Glycomet 500 mg SR. Concomitant use of other antidiabetic agents, certain contrast agents, or medications that affect renal perfusion may necessitate dose modification or temporary discontinuation of therapy. Alcohol consumption should be limited, as it can increase the risk of lactic acidosis. Regular laboratory tests, including renal function and vitamin B12 levels, are recommended during long‑term treatment. If surgical procedures requiring anesthesia are planned, the drug should be paused for at least 48 hours to reduce the potential for metabolic disturbances.

Frequently Asked Questions

1. What is the difference between Glycomet SR and regular Glycomet? Glycomet SR (sustained‑release) and standard Glycomet contain the same active ingredient, metformin, but differ in their release profile. The SR formulation releases the drug gradually over approximately 24 hours, allowing a once‑daily dosing schedule and smoother plasma concentrations. Regular Glycomet is immediate‑release and typically requires two or three daily doses to maintain therapeutic levels. This pharmacokinetic distinction can reduce gastrointestinal side effects and improve adherence, while providing comparable glycemic control when used as directed.
2. Can Glycomet be used in patients with kidney disease? Metformin is primarily eliminated through the kidneys, so dose adjustments are recommended for patients with impaired renal function. Glycomet 500 mg SR is generally not advised for individuals with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², and caution is warranted when eGFR falls between 30 and 45 mL/min. In such cases, a lower starting dose or an alternative antidiabetic agent may be preferred. Always consult a physician before initiating or continuing therapy if renal function is compromised.
3. How long does it take to see a reduction in HbA1c? The glycemic response to metformin SR is typically observable within the first few weeks of therapy, with a measurable decline in fasting plasma glucose. However, the full effect on glycated hemoglobin (HbA1c) usually becomes evident after 8 to 12 weeks of consistent daily use, especially when combined with dietary modifications and exercise. Individual variability, baseline glucose levels, and adherence influence the timeline. Regular monitoring by a healthcare professional helps assess progress and determine whether dose adjustments are needed to achieve target glucose control.
4. Is Glycomet safe during pregnancy or breastfeeding? Glycomet 500 mg SR is not recommended for use during pregnancy or lactation unless specifically prescribed by a qualified physician. Metformin crosses the placental barrier and may affect fetal development, and its presence in breast milk could influence infant metabolism. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their doctor. If pregnancy occurs while taking the medication, it should be discontinued and medical advice sought promptly.
5. Can I take Glycomet with other medications? Yes, Glycomet 500 mg SR can be used in combination with several other antidiabetic agents, including sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors, depending on individual glycemic goals and tolerability. However, concurrent use with other metformin-containing products must be avoided to prevent excessive dosing. It is also important to review potential drug‑drug interactions with medications that affect renal function, contrast agents, or certain anesthetic agents. Always inform your healthcare provider about all prescription, over‑the‑counter, and herbal products you are using.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)